An approach to breast cancer diagnosis via PET imaging of microcalcifications using 18F-NaF

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1138-1143

  Wilson III, George H ^a   Gore, John C ^a,b,c,d   Yankeelov, Thomas E ^a,b,c,d   Barnes, Stephanie ^a,b   Peterson, Todd E ^a,b   True, Jarrod M ^a   Shokouhi, Sepideh ^a,b   McIntyre, J Oliver ^a,b,c,d   Sanders, Melinda ^b   Abramson, Vandana ^b   Ngyuen, The Quyen ^c   Mahadevan Jansen, Anita ^c   Tantawy, Mohammed N ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Calcium oxalate; Hydroxyapatite; MDA MB 231; Microcalcification; PET

Indexed keywords

ALIZARIN RED S; HYDROXYAPATITE; SODIUM FLUORIDE F 18; FLUORINE; SODIUM FLUORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BREAST CALCIFICATION; BREAST CANCER; BREAST CANCER CELL LINE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST SENSITIVITY; CONTRAST TO NOISE RATIO; EARLY DIAGNOSIS; FEMALE; HISTOLOGY; IN VIVO STUDY; INFLAMMATION; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAMAN SPECTROMETRY; RAT; SENSITIVITY ANALYSIS; STAINING; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BREAST TUMOR; CALCINOSIS; COMPLICATION; HUMAN; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CALCINOSIS; CELL LINE, TUMOR; DURAPATITE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; SODIUM FLUORIDE;

EID: 84904110648     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.139170     Document Type: Article

References (33)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-418.
2. Bruening W, Uhl S, Fontanarosa J, Reston J, Treadwell J, Schoelles K. Noninvasive Diagnostic Tests for Breast Abnormalities: Update of a 2006 Review - Comparative Effectiveness Review No. 47. Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ publication 12-EHC014-EF.
3. Gershon-Cohen J. The importance of x-ray microcalcifications in breast cancer. AJR. 1967;99:1010-1011.
4. Baker R, Rogers KD, Shepard N, Stone N. New relationships between breast microcalcifications and cancer. Br J Cancer. 2010;103:1034-1039.
5. Going JJ, Anderson TJ, Crocker PR, Levison DA. Weddellite calcification in the breast: eighteen cases with implications for breast cancer screening. Histopathology. 1990;16:119-124. (Pubitemid 20123355)
6. Haka AS, Shafer-Peltier KE, Fitzmaurice M, Crowe J, Dasari RR, Feld MS. Identifying microcalcifications in benign and malignant breast lesions by probing differences in their chemical composition using Raman spectroscopy. Cancer Res. 2002;62:5375-5380. (Pubitemid 35024616)
7. Morgan MP, Cooke MM, Christopherson PA, Westfall PR, McCarthy GM. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines. Mol Carcinog. 2001;32:111-117. (Pubitemid 33055000)
8. Cox RF, Hernandez-Santana A, Ramdass S, McMahon G, Harmey JH, Morgan MP. Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br J Cancer. 2012;106:525-537.
9. Pleshko N, Boskey A, Mendelsohn R. Novel infrared spectroscopic method for the determination of crystallinity of hydroxyapatite minerals. Biophys J. 1991;60:786-793.
10. Nelson DG. The influence of carbonate on the atomic structure and reactivity of hydroxyapatite. J Dent Res. 1981;60 spec no C:1621-1629.
11. Hawkins RA, Hoh C, Glaspy J, et al. The role of positron emission tomography in oncology and other whole-body applications. Semin Nucl Med. 1992;22:268-284.
12. 18F-NaF deposition. J Nucl Med. 2010;51:1826-1829.
13. Korah RM, Sysounthone V, Golowa Y, Wieder R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res. 2000;60:733-740. (Pubitemid 30094575)
14. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999;59:80-84. (Pubitemid 29062961)
15. Uddin MJ, Crews BC, Ghebreselasie K, et al. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila). 2011;4:1536-1545.
16. Nelson DG, Featherstone JD. Preparation, analysis, and characterization of carbonated apatites. Calcif Tissue Int. 1982;34(suppl 2):S69-S81. (Pubitemid 13218762)
17. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
18. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31-37.
19. Schmid HA, Requintina PJ, Oxenkrug GF, Sturner W. Calcium, calcification, and melatonin biosynthesis in the human pineal gland: a postmortem study into age-related factors. J Pineal Res. 1994;16:178-183.
20. Krstić R, Golaz J. Ultrastructural and x-ray microprobe comparison of gerbil and human pineal acervuli. Experientia. 1977;33:507-508. (Pubitemid 8075373)
21. Alcolado JC, Moore IE, Weller RO. Calcification in the human choroid plexus, meningiomas and pineal gland. Neuropathol Appl Neurobiol. 1986;12:235-250. (Pubitemid 16079846)
22. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992;327:1141-1152.
23. Lemann J Jr. Composition of the diet and calcium kidney stones. N Engl J Med. 1993;328:880-882.
24. Parmar MS. Kidney stones. BMJ. 2004;328:1420-1424. (Pubitemid 38789199)
25. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367:333-344. (Pubitemid 43151467)
26. Low RK, Ho S, Stoller ML. Sodium fluoride dissolution of human calcium oxalate/phosphate stone particles. J Endourol. 1995;9:379-382.
27. Cook GJ. Oncological molecular imaging: nuclear medicine techniques. Br J Radiol. 2003;76(spec no 2):S152-S158. (Pubitemid 39530308)
28. 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813-1820.
29. Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008;112:2130-2142. (Pubitemid 351628621)
30. Moran M, Haffty BG. Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys. 1998;40:353-358. (Pubitemid 28114380)
31. Aulmann S, Penzel R, Schirmacher P, Sinn HP. Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer [in German]. Verh Dtsch Ges Pathol. 2007;91:208-213.
32. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501-505.
33. 18F-fluoride PET images of breast cancer bone metastases. J Nucl Med. 2010;51:521-527.